Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$4,451 Mln
P/E Ratio
12.27
P/B Ratio
3.04
Industry P/E
--
Debt to Equity
0.05
ROE
0.28 %
ROCE
23.56 %
Div. Yield
0 %
Book Value
8.66
EPS
2.17
CFO
$704.48 Mln
EBITDA
$-213.72 Mln
Net Profit
$-921.08 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Alkermes (ALKS)
| -5.60 | -21.53 | -10.13 | 12.80 | 1.18 | 12.66 | -7.34 |
|
BSE Sensex*
| 1.97 | 3.75 | 4.27 | 8.21 | 11.74 | 20.15 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Alkermes (ALKS)
| 14.20 | 12.34 | 16.59 | -2.21 | -30.87 | -45.90 | -1.53 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 9.50 | 568.80 | -- | -19.58 | |
| 1.39 | 35.62 | -- | 472.61 | |
| 9.59 | 500.59 | -- | -23.34 |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of... proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Address: Connaught House, Dublin, Ireland, D04 C5Y6 Read more
Chairman & CEO
Mr. Richard F. Pops
Chairman & CEO
Mr. Richard F. Pops
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Alkermes plc (ALKS) stood at $ 2,056 Mln as on 31-Dec-24
The share price of Alkermes plc (ALKS) is $27.15 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Alkermes plc (ALKS) has given a return of 1.18% in the last 3 years.
Alkermes plc (ALKS) has a market capitalisation of $ 4,451 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Alkermes plc (ALKS) is 12.27 times as on 22-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Alkermes plc (ALKS) and enter the required number of quantities and click on buy to purchase the shares of Alkermes plc (ALKS).
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Address: Connaught House, Dublin, Ireland, D04 C5Y6
The CEO & director of Mr. Richard F. Pops. is Alkermes plc (ALKS), and CFO & Sr. VP is Mr. Richard F. Pops.
There is no promoter pledging in Alkermes plc (ALKS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
76
|
|
|
45
|
|
|
5
|
|
|
76
|
| Alkermes plc (ALKS) | Ratios |
|---|---|
|
Return on equity(%)
|
27.52
|
|
Operating margin(%)
|
29.94
|
|
Net Margin(%)
|
23.57
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Alkermes plc (ALKS) was $0 Mln.
$0.04
(
